Head to Head Contrast: Bausch Health Cos (NYSE:BHC) vs. ImmuCell (NASDAQ:ICCC)

ImmuCell (NASDAQ:ICCC) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for ImmuCell and Bausch Health Cos, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0	1	0	0	2.00
Bausch Health Cos	1	5	0	1	2.14

Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 37.81%. Given Bausch Health Cos’ stronger consensus rating and higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than ImmuCell.

Valuation and Earnings

This table compares ImmuCell and Bausch Health Cos”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64 million	3.28	-$1.04 million	$0.08	124.88
Bausch Health Cos	$10.27 billion	0.21	$157.00 million	($2.96)	-1.96

Bausch Health Cos has higher revenue and earnings than ImmuCell. Bausch Health Cos is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ImmuCell has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Institutional and Insider Ownership

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ImmuCell and Bausch Health Cos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Summary

Bausch Health Cos beats ImmuCell on 8 of the 14 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

About Bausch Health Cos

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.